Tracers / [18F]AlF-NOTA-DV1-k-(DV3)

[18F]AlF-NOTA-DV1-k-(DV3)

Also written as [F-18]AlF-NOTA-DV1-k-(DV3)
Radionuclide
F-18 t½ 109.77 min
Modality
Therapy
Production route
Stage
Reported once
Syntheses indexed
1

What it is

Compound class
CXCR4-targeting D-peptide-based radiopharmaceutical (NOTA-conjugated)
Target / mechanism
CXCR4 (C-X-C chemokine receptor 4) PMID 34683912
Clinical application
CXCR4-targeted molecular imaging and radionuclide therapy (patient selection for CXCR4-directed therapy) PMID 34683912
Theranostic pair

Regulatory status

FDA
EMA (centralised)
Other approvals
Brand names

Clinical use

Typical injected activity
Uptake time

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
AllinOne (AiO)
Trasis
vendor cassetteHPLC26 ± 6%
yes
>98%NOTA-DV1-k-(DV3)
Pepmic Co., Ltd., Suzhou, China
34683912
2021 Pharmaceutics
NOTA-DV1-k-(DV3) was labeled using the Al18F-method in an AllInOne® synthesis module (Trasis, Ans, Belgium) [17]. — [18F]AlF-NOTA-DV1-k-(DV3) was successfully produced in high yield (26 ± 6% (decay-corrected, activity in reactor/activity final batch of purified product, n = 6)

Need this precursor?We can point you to suppliers for [18F]AlF-NOTA-DV1-k-(DV3), or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 34683912. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 34683912: 'NOTA-DV1-k-(DV3)'. | Stage 26: Name corrected from '[18F]AlF-NOTA-DV1-k-(DV3' to '[18F]AlF-NOTA-DV1-k-(DV3)' -- matches the precursor name already on file from PMID 34683912 ('NOTA-DV1-k-(DV3)'): missing closing parenthesis restored.